

# **SANA Biotechnology**

Fact Sheet

**S A N A**

**L I S T E D**

**N A S D A Q**

# SANA BIOTECHNOLOGY

## QUICK REFERENCE

Sana Biotechnology Inc.

**NASDAQ: SANA**

Website: [www.SANA.com](http://www.SANA.com)

## BUSINESS SUMMARY

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA.

## OUR SCIENCE

Scientists have made tremendous progress over the past decade in understanding how to modulate genes and use them now to make transformative medicines. The first wave of these transformative medicines has recently launched or is on pace to reach patients soon. However, the field is still in its infancy.

Assembling the right technologies is key to opening up therapeutic opportunities ranging from rare diseases caused by a single genetic mutation to acquired diseases that affect millions.

In our work, three aspirations guide us:

1. Developing the ability to repair any cell in the body
2. Developing the ability to replace any cell in the body
3. Developing the technologies and processes to enable access to our therapies

## PIPELINE

Our most advanced programs include an allogeneic CAR T program for B-cell mediated autoimmune diseases (SC291), an allogeneic CAR T program targeting CD22+ cancers (SC262), and a stem cell-derived pancreatic islet cell program for persons with type 1 diabetes (SC451).

**Product Candidate:** SC291 (CD19)

Cell Type: T cells

Potential Indications: Autoimmune Diseases; (i) Lupus nephritis, (ii) Extrarenal SLE, (iii) ANCA-associated vasculitis (AAV)

Phase 1: GLEAM is a Phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, for severe r/r B-cell mediated autoimmune diseases.

**Product Candidate:** SC262 (CD22)

Cell Type: T cells

Potential Indications: Oncology; (i) Non-Hodgkin lymphoma (NHL); (ii) Acute lymphoblastic leukemia (ALL); (iii) Chronic lymphocytic leukemia (CLL)

Phase 1: VIVID is a Phase 1 study evaluating SC262, a hypoimmune allogeneic CD22-directed CAR T cell therapy, for r/r B-cell malignancies.

## CONTACT INFORMATION

US Headquarters  
188 East Blaine Street  
Seattle, WA 98102

Barwicki Investor Relations  
Andrew Barwicki  
516-662-9461/[andrew@barwicki.com](mailto:andrew@barwicki.com)

## Recent Press Releases *(Headline and Excerpts)*

### **Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus**

- ***Fast Track designation is designed to expedite clinical development and regulatory review timelines***
- ***Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025***

Dec. 02, 2024 -- Sana Biotechnology, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

SC291, a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana's GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2025.

SC291 is a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform. Our allogeneic T cell programs use T cells from healthy donors to generate CAR T therapies that, in this case, target CD19, a protein expressed on the cell surface of B cells. B cells drive disease pathology in many autoimmune diseases, and therapies that target B cells have been efficacious across multiple autoimmune diseases. Emerging data in the field support the concept that deeper tissue B cell depletion can be associated with greater efficacy and a reasonable safety profile. CD19-directed CAR T therapy introduces a new option, in which the CAR T is the effector cell that depletes B cells throughout the body. Our goal is to develop SC291 in various settings, using our existing hypoimmune allogeneic CAR T manufacturing platform, to deliver with scale for these large unmet needs.

### **Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates**

- ***Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology***
- ***Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025***
- ***Announced increased focus on type 1 diabetes and B-cell mediated autoimmune diseases***
- ***Cash position of \$199.0 million with expected cash runway into 2026***

SEATTLE, Nov. 08, 2024 -- Sana Biotechnology, Inc. today reported financial results and business highlights for the third quarter 2024.

Payments related to ongoing activities combined with the strategic repositioning may increase the 2024 operating cash burn above prior guidance of less than \$200 million.

#### Recent Corporate Highlights

Advancing three clinical programs across five indications, including a gene-modified primary islet cell therapy in type 1 diabetes, an allogeneic CAR T program for B-cell mediated autoimmune diseases, and an allogeneic CAR T program for cancer patients that have failed a CD19-targeted therapy:

- **Type 1 Diabetes** – UP421 is a primary human HIP-modified pancreatic islet cell therapy for patients with type 1 diabetes. The goal of this investigator-sponsored trial (IST) is to understand immune evasion, islet cell survival, and beta cell function, as measured by C-peptide production, of HIP-modified pancreatic islet cells in type 1 diabetics without any immunosuppression. Sana expects to share initial data in 2024 and/or 2025. Sana is also making progress with the pre-clinical development of SC451, a HIP-modified, stem cell-derived pancreatic islet cell program.
- **B-cell Mediated Autoimmune Diseases** – The GLEAM trial evaluates SC291, a HIP-modified CD19-directed allogeneic CAR T therapy, in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2024 and/or 2025.
- **Oncology** – The VIVID trial evaluates SC262, a HIP-modified CD22-directed allogeneic CAR T therapy, in patients with relapsed or refractory B-cell malignancies who have received prior CD19-directed CAR T therapy. Sana is enrolling patients and expects to share data in 2025.

Strengthened Research and Development leadership with the appointment of new Chief Scientific Officer

Appointed Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Patel has decades of experience in research, drug discovery, drug development, and clinical care – including roles at UCB, Novartis, University of North Carolina, and the Duke University School of Medicine – and over the course of his career has participated in the development of 10 approved drugs in multiple indications.

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / andrew@barwicki.com

The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, internet, company website and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Standard Mail  
U.S. Postage Paid  
Garden City, NY  
Permit No. 431

# **Sana Biotechnology Inc.**

**NASDAQ: SANA**

**WWW.SANA.COM**

---

Barwicki Investor Relations \* 30 Wall Street, 8 FL \* New York, NY 10005

Deliver to: